117 related articles for article (PubMed ID: 21825987)
1. Fabry disease.
Toyooka K
Curr Opin Neurol; 2011 Oct; 24(5):463-8. PubMed ID: 21825987
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease.
Toyooka K
Handb Clin Neurol; 2013; 115():629-42. PubMed ID: 23931807
[TBL] [Abstract][Full Text] [Related]
3. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.
Schiffmann R
Acta Neurol Belg; 2006 Jun; 106(2):61-5. PubMed ID: 16898255
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
[TBL] [Abstract][Full Text] [Related]
5. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
6. Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease.
Tavakoli M; Marshall A; Thompson L; Kenny M; Waldek S; Efron N; Malik RA
Muscle Nerve; 2009 Dec; 40(6):976-84. PubMed ID: 19902546
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
8. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.
Hilz MJ; Brys M; Marthol H; Stemper B; Dütsch M
Neurology; 2004 Apr; 62(7):1066-72. PubMed ID: 15079003
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
11. [Neurological complications of Fabry-disease].
Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
[TBL] [Abstract][Full Text] [Related]
12. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.
Machann W; Breunig F; Weidemann F; Sandstede J; Hahn D; Köstler H; Neubauer S; Wanner C; Beer M
Eur J Heart Fail; 2011 Mar; 13(3):278-83. PubMed ID: 21149315
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
14. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
15. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
16. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
17. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
18. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
[TBL] [Abstract][Full Text] [Related]
19. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
20. Small fiber neuropathy in female patients with fabry disease.
Liguori R; Di Stasi V; Bugiardini E; Mignani R; Burlina A; Borsini W; Baruzzi A; Montagna P; Donadio V
Muscle Nerve; 2010 Mar; 41(3):409-12. PubMed ID: 20120004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
